scholarly journals A case of feline large granular lymphocyte lymphoma with complete remission and long survival by surgical resection and adjuvant nimustine administration

2021 ◽  
Author(s):  
Makoto Akiyoshi ◽  
Masami Akiyoshi
Keyword(s):  
Complete Remission ◽  
Surgical Resection ◽  
Large Granular Lymphocyte ◽  
Long Survival

scholarly journals Four cases with advanced hepatocellular carcinoma who achieved long survival, after surgical resection following to down-staging therapies

Kanzo ◽  
2016 ◽  
Vol 57 (12) ◽  
pp. 649-655 ◽  
Author(s):  
Hitomi Takada ◽  
Kaoru Tsuchiya ◽  
Natsuko Nakakuki ◽  
Nobuharu Tamaki ◽  
Yutaka Yasui ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Surgical Resection ◽  
Advanced Hepatocellular Carcinoma ◽  
Long Survival

Concomitant Presentation of Acute Myeloid Leukemia (AML) and Lung Cancer

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3994-3994
Author(s):  
Ramya Varadarajan ◽  
LaurieAnn Ford ◽  
Sheila NJ Sait ◽  
Annemarie W. Block ◽  
Maurice Barcos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Risk Factor ◽  
Complete Remission ◽  
Surgical Resection ◽  
Median Survival ◽  
Allogeneic Transplantation ◽  
Smoking History ◽  
Roswell Park Cancer Institute ◽  
Adjuvant Radiation ◽  
Refractory Disease

Abstract Smoking is associated with AML and lung cancer, suggesting a common carcinogenic origin and raising the question of how to treat patients with concomitant cancer presentations. The Roswell Park Cancer Institute Tumor Registry was searched for patients with both diagnoses, followed by medical record review. Among 775 AML cases and 5225 lung cancer cases presented to Roswell Park Cancer Institute between January 1992 and May 2008 we identified twelve patients with both AML and lung cancer (1.5% of AML cases; 0.2% of lung cancer cases). Of these, seven cases had metachronous and five cases had synchronous presentation. Eleven of the twelve (92%) patients had a known smoking history; five (42%) of them were males. The median age at the respective diagnoses was 65 (range 58–85) years for AML and 66 (range 53–79) years for lung cancer. Five of the twelve (42%) patients had a complex karyotype. Metachronous group: Lung cancer preceded AML in six patients by a median interval of eight (range five-14) years, while AML preceded the diagnosis of lung cancer in one patient by three years. For their lung cancer, five patients had surgical resection. Two had definitive chemoradiation, one patient had adjuvant chemotherapy and one patient had adjuvant radiation suggesting that their subsequent AML was secondary. Two patients had preceding MDS even though they underwent only surgical resection for their lung cancer. For their AML, five of the seven patients were treated with cytarabine and anthracycline-containing regimens; two achieved complete remission, two had primary refractory disease and one patient died during induction. One patient with primary refractory disease underwent sibling matched allogeneic transplantation and is still alive in remission. The median survival for lung cancer was 65 (range 22–120) months. The median survival since AML diagnosis was less than one (range <1–105) month. Five of the seven patients died from AML complications, one patient died of an unrelated cause and one patient is alive in remission. Synchronous group: All five patients were treated initially for AML with cytarabine and anthracycline-containing regimens; two achieved complete remission, two had refractory disease and one patient had prolonged cytopenia. Two patients underwent surgical resection for their lung cancer after treatment for AML and one had palliative radiation. The median survival was five (range three-21) months and four of the five patients died of AML related causes. Conclusions: Less than 2% of AML patients present with lung cancer. Prior chemoradiation for non small cell lung cancer may be a risk factor for secondary AML but does not explain development of AML in the majority of patients, suggesting a potential role of prior tobacco use as a common carcinogenic risk factor. Although AML and lung cancers both carry poor prognoses, our data imply that AML has a more aggressive course than lung cancer and is the main cause of mortality in these patients. This miniseries highlights again the need for enforcing smoking cessation.

Non-Hodgkin's lymphoma of the stomach: a prospective pilot study of surgery plus chemotherapy in early and advanced disease.

1985 ◽  
Vol 3 (4) ◽  
pp. 495-500 ◽  
Author(s):  
W P Sheridan ◽  
G Medley ◽  
G N Brodie
Keyword(s):  
Pilot Study ◽  
Complete Remission ◽  
Surgical Resection ◽  
Hodgkin’S Lymphoma ◽  
Advanced Disease ◽  
Hodgkin's Lymphoma ◽  
Prospective Pilot Study ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Disease Free

A prospective pilot study of 23 patients with non-Hodgkin's lymphoma involving the stomach was undertaken to assess the efficacy of surgical resection followed by chemotherapy with adjuvant cyclical cyclophosphamide, vincristine, and prednisolone (CVP) in early stage disease, and cyclical cyclophosphamide, vincristine, prednisolone, and doxorubicin (CHOP) in advanced disease. One of 18 evaluable patients died postoperatively; 17 of 18 completed therapy and are alive and disease-free at a median follow-up of 41 months after surgery (range, 5 to 111 months), including four patients with stage IV disease who remain in complete remission 19 to 47 months after surgery. There was one postoperative death, giving an actuarial survival rate of 94% in the study group. Three of five inoperable patients were treated with CHOP, with two achieving complete remission. Two untreated patients died. Overall actuarial disease-free survival was 82.6%. Surgical resection plus chemotherapy is capable of producing long-term remission and cure in both localized and advanced non-Hodgkin's lymphoma of the stomach. Intensive supportive care plus chemotherapy may salvage a proportion of patients with inoperable tumors.

Prognostic influence of waiting time in management of pancreatic ductal adenocarcinoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15726-e15726
Author(s):  
Rei Suzuki ◽  
Tadayuki Takagi ◽  
Takuto Hikichi ◽  
Hiromasa Ohira
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Surgical Resection ◽  
Waiting Time ◽  
Waiting Times ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Ductal Adenocarcinoma ◽  
Survival Group ◽  
Long Survival

e15726 Background: Since pancreatic ductal adenocarcinoma (PDAC) showed aggressive progression, we hypothesized that waiting time in management might have prognostic influence on patients’ prognosis. Methods: Data on PDAC patients who underwent either chemotherapy or surgical resection in our hospital (2006 – 2016) were collected. Waiting time was classified into two groups as detection-to-diagnosis waiting time (WT1) and diagnosis-to-treatment waiting time (WT2). Median disease free survival (DFS) and overall survival (OS) were calculated by Kaplan-Meier method and utilized as cut-off points to divide patients into 2 groups (short- and long-survival group). Clinical characteristics including age, sex, tumor size, location of tumor, stage of disease, the levels of serum tumor markers, waiting times, use of adjuvant chemotherapy and resectability were compared between the two survival groups. Results: In total, 149 patients were included. Seventy-two patients who underwent chemotherapy (median OS: 9.7 months) were divided into long survival group (n = 42) and short survival group (n = 30). We did not find significant differences in both WT1 (20.0 days vs. 19.0 days, P = 0.98) and WT2 (17.0 days vs. 18.5 days, P = 0.93), while proportion of patients with locally advanced disease ( P = 0.02) and combination chemotherapy ( P = 0.003) was significantly associated with long survival. Among 79 patients underwent surgical resection, median DFS after pancreatic resection was 16.4 months and OS was 35.0 months. The patients were divided into short DFS (n = 47) versus long DFS (n = 30) and short OS (n = 57) versus long OS (n = 20). We did not find significant differences in both WT1 (short vs. long DFS: 21.0 days vs. 21.0 day, P = 0.65, short vs. long OS: 21.0 days vs. 23.0 days, P = 0.45) and WT2 (short vs. long DFS: 46.0 days vs. 44.5 days, P = 0.45, short vs. long OS: 46.0 vs. 41.0 days, P = 0.36). Both advanced T- and N-stage was significantly associated with poor DFS ( P = 0.049, P = 0.03, respectively) while only advanced T-stage was significantly associated with poor OS ( P = 0.02). Conclusions: Our findings suggested that both detection-to-diagnosis waiting time and diagnosis-to-treatment waiting time might not influence on prognosis of patients with PDAC.

Monitoring of a Long Survival Myeloma Patient

1981 ◽  
Vol 67 (6) ◽  
pp. 571-573 ◽  
Author(s):  
Mario Boccadoro ◽  
Annette Van Acker ◽  
Anna Carmagnola ◽  
Franco Conte ◽  
Alessandro Pileri
Keyword(s):  
Complete Remission ◽  
B Lymphocytes ◽  
Plasma Cells ◽  
Great Majority ◽  
Labeling Index ◽  
Therapeutic Management ◽  
Myeloma Patient ◽  
Long Survival ◽  
Tumoral Cells

Monitoring with anti-idiotypic sera has been applied to identify tumoral cells in a myeloma patient still alive in complete remission 9 years after diagnosis. Monoclonal plasma cells displayed a labeling index that decreased in complete remission below 1 %. The great majority of B lymphocytes belonged to the tumoral clone even in complete remission and were therefore not affected by conventional chemothrapy. Some aspects of this myeloma patient are discussed in the light of these immunologic and kinetic findings. In addition, it is suggested that the therapeutic management of the complete remission should be re-examined, by considering a lymphocytolytic therapy.

scholarly journals Complete Remission of Associative Immune-Mediated Hemolytic Anemia in a Dog Following Surgical Resection of Intestinal Leiomyosarcoma

2019 ◽  
Vol 6 (2) ◽  
pp. 55
Author(s):  
Masashi Yuki ◽  
Eiji Naitoh
Keyword(s):  
Complete Remission ◽  
Surgical Resection ◽  
Hemolytic Anemia ◽  
Immunosuppressive Treatment ◽  
Abdominal Ultrasound ◽  
Direct Antiglobulin Test ◽  
Intestinal Neoplasm ◽  
Immune Mediated ◽  
Antiglobulin Test ◽  
Veterinary Hospital

A twelve-year-old male castrated Chihuahua with a severe, microcytic, hypochromic, and nonregenerative direct antiglobulin test positive anemia characterized by marked spherocytosis was referred to the veterinary hospital. Abdominal ultrasound revealed a peritoneal mass of unclear origin. Transfusion, followed by mass resection, rapidly resolved the anemia without further immunosuppressive treatment. Histopathology confirmed extraluminal jejunal leiomyosarcoma. Multiple mechanisms, including immune-mediated destruction, likely contributed to the anemia. To the authors’ knowledge, this is the first report that describes the resolution of immune-mediated hemolysis in a dog after the removal of an intestinal neoplasm.

scholarly journals A Case Report of Successful Management with Long Term Survival of Basal Cell Carcinoma of the Internal Canthus of the Right Eye

2021 ◽  
pp. 1-5
Author(s):  
Mohamed Réda Khmamouche ◽  
Mohamed Réda Khmamouche ◽  
Mehdi Khmamouche ◽  
Mohamed Amine Essaoudi ◽  
Tarik Mahfoud ◽  
...  
Keyword(s):  
Case Report ◽  
Complete Remission ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Surgical Resection ◽  
Basal Cell ◽  
Successful Management ◽  
Term Survival ◽  
The Right

Basal cell carcinoma (BCC) is the most frequently occurring malignant periocular tumor. The aim of treatment remains surgery with negative margins. We report a case of 65-year-old woman who was diagnosed with BCC of internal canthus of the right eye, in October 2011. The patient was treated by surgical resection in 2 steps with reconstruction by a frontal flap. The treatment resulted in complete remission without any recurrence after ten years of surgery.

Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia

2018 ◽  
Vol 60 (1) ◽  
pp. 254-257
Author(s):  
Claire Lozano ◽  
Sophie Brun ◽  
Anne Arnaud ◽  
Philippe Gaulard ◽  
Samia Gonzalez ◽  
...  
Keyword(s):  
T Cell ◽  
Complete Remission ◽  
Large Granular Lymphocyte ◽  
Variant Form ◽  
Large Granular Lymphocyte Leukemia

scholarly journals Complete Remission with Transarterial Chemoembolization in a Patient with Hepatocellular Carcinoma Who Showed Early Recurrence following Surgical Resection

2018 ◽  
Vol 18 (2) ◽  
pp. 162-167
Author(s):  
Hee Yeon Kim ◽  
Chang Wook Kim ◽  
Sungkeun Kim ◽  
Soo Lim Lee ◽  
Young Mi Ku ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Complete Remission ◽  
Surgical Resection ◽  
Transarterial Chemoembolization ◽  
Early Recurrence
Sign in / Sign up

Export Citation Format

Share Document